TN2009000408A1 - Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor - Google Patents

Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor

Info

Publication number
TN2009000408A1
TN2009000408A1 TNP2009000408A TN2009000408A TN2009000408A1 TN 2009000408 A1 TN2009000408 A1 TN 2009000408A1 TN P2009000408 A TNP2009000408 A TN P2009000408A TN 2009000408 A TN2009000408 A TN 2009000408A TN 2009000408 A1 TN2009000408 A1 TN 2009000408A1
Authority
TN
Tunisia
Prior art keywords
inhibitor
acts
factor
compound
anticoagulant therapy
Prior art date
Application number
TNP2009000408A
Other languages
English (en)
French (fr)
Inventor
Uma Sinha
Stanley J Hollenbach
Patrick Andre
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of TN2009000408A1 publication Critical patent/TN2009000408A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
TNP2009000408A 2007-04-13 2009-10-09 Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor TN2009000408A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91185207P 2007-04-13 2007-04-13
PCT/US2008/004760 WO2008127682A2 (en) 2007-04-13 2008-04-11 Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor

Publications (1)

Publication Number Publication Date
TN2009000408A1 true TN2009000408A1 (en) 2011-03-31

Family

ID=39638994

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000408A TN2009000408A1 (en) 2007-04-13 2009-10-09 Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor

Country Status (16)

Country Link
US (3) US20080254036A1 (cg-RX-API-DMAC7.html)
EP (2) EP2155195B1 (cg-RX-API-DMAC7.html)
JP (2) JP5469595B2 (cg-RX-API-DMAC7.html)
KR (1) KR101473207B1 (cg-RX-API-DMAC7.html)
CN (2) CN101743001B (cg-RX-API-DMAC7.html)
AU (1) AU2008239659B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0809655B8 (cg-RX-API-DMAC7.html)
CA (1) CA2683793C (cg-RX-API-DMAC7.html)
DO (1) DOP2009000244A (cg-RX-API-DMAC7.html)
EA (1) EA020531B1 (cg-RX-API-DMAC7.html)
GT (1) GT200900260A (cg-RX-API-DMAC7.html)
IL (1) IL201433A (cg-RX-API-DMAC7.html)
MX (1) MX2009010953A (cg-RX-API-DMAC7.html)
NZ (1) NZ580162A (cg-RX-API-DMAC7.html)
TN (1) TN2009000408A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008127682A2 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE311366T1 (de) * 2000-02-29 2005-12-15 Millennium Pharm Inc Benzamide und ähnliche inhibitoren vom faktor xa
CA2565437A1 (en) * 2004-06-18 2006-01-05 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
WO2007112367A2 (en) * 2006-03-27 2007-10-04 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
EP2016072B1 (en) 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
PT2404906E (pt) * 2006-11-02 2015-11-02 Millennium Pharm Inc Métodos de sintetizar sais farmacêuticos de um inibidor de fator xa
JP2010515691A (ja) * 2007-01-05 2010-05-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 第Ｘａ因子阻害剤
NZ581324A (en) * 2007-05-02 2012-05-25 Portola Pharm Inc Combination therapy with a compound acting as a platelet adp receptor inhibitor
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112012011298B1 (pt) 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
JP5766204B2 (ja) 2009-12-17 2015-08-19 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 第Ｘａ因子阻害剤の合成方法
US8530501B2 (en) * 2009-12-17 2013-09-10 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor Xa inhibitor
US8742120B2 (en) 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
EP2515871B1 (en) * 2009-12-23 2015-09-23 ratiopharm GmbH Solid pharmaceutical dosage form of ticagrelor
US20120052058A1 (en) * 2010-08-30 2012-03-01 Emory University Methods of managing the blood coagulation and pharmaceutical compositions related thereto
TW201240664A (en) * 2010-09-01 2012-10-16 Portola Pharm Inc Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor
TW201221128A (en) 2010-09-01 2012-06-01 Portola Pharm Inc Crystalline forms of a factor Xa inhibitor
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US20140346397A1 (en) 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US10603316B2 (en) 2013-08-21 2020-03-31 Morehouse School Of Medicine Composition and methods for preventing or reducing the incidence of transient ischemic attacks
US10471163B2 (en) 2013-09-13 2019-11-12 The General Hospital Corporation Activatable fibrin-binding probes
TW201613581A (en) * 2014-09-02 2016-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition for suppression of thromboembolization after stent placement
WO2017091757A1 (en) 2015-11-24 2017-06-01 Portola Pharmaceuticals, Inc. Isotopically enriched betrixaban
US20190300483A1 (en) * 2016-06-02 2019-10-03 Dr. Reddy's Laboratories Limited POLYMORPHS OF BETRlXABAN & ITS MALEATE SALT
BR112019022676A2 (pt) 2017-06-23 2020-05-19 Chiesi Farm Spa método de prevenção de trombose de derivação da artéria sistêmica-para-pulmonar
WO2020047097A1 (en) * 2018-08-28 2020-03-05 Morehouse School Of Medicine Composition and methods for preventing or reducing the incidence of transient ischemic attacks
CN116782911A (zh) * 2020-09-17 2023-09-19 艾克赛特赫拉制药有限责任公司 治疗性化合物、组合物及其使用方法
EP4070658A1 (de) * 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1384725A3 (en) 1994-04-26 2007-02-21 Aventis Pharmaceuticals Inc. Factor Xa inhibitors
SK285529B6 (sk) * 1998-11-27 2007-03-01 Basf Aktiengesellschaft Substituované benzimidazoly, farmaceutická kompozícia s ich obsahom a ich použitie ako inhibítorov PARP
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
NZ517828A (en) * 1999-09-17 2003-10-31 Millennium Pharm Inc Inhibitors having activity against mammalian factor Xa
HK1052497B (zh) * 1999-09-17 2007-03-02 千禧药品公司 苯甲酸胺和相关的因子xa抑制剂
US6844367B1 (en) * 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
ATE311366T1 (de) 2000-02-29 2005-12-15 Millennium Pharm Inc Benzamide und ähnliche inhibitoren vom faktor xa
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
US20040192753A1 (en) 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7235567B2 (en) 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US6686193B2 (en) * 2000-07-10 2004-02-03 Vertex Pharmaceuticals, Inc. High throughput method and system for screening candidate compounds for activity against target ion channels
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
HRP20000765A2 (en) 2000-11-10 2002-06-30 Pliva D D Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
DE10065475A1 (de) * 2000-12-28 2002-07-18 Switch Biotech Ag Verwendung von "intermediate-conductance" Kaliumkanälen und Modulatoren zur Diagnose und Behandlung von Krankheiten mit gestörter Keratinozytenfunktion
US20030114371A1 (en) * 2001-02-07 2003-06-19 Feder John N. Polynucleotide encoding a novel human potassium channel beta-subunit, K+betaM3
US7312235B2 (en) * 2001-03-30 2007-12-25 Millennium Pharmaceuticals, Inc. Benzamide inhibitors of factor Xa
WO2003028840A2 (en) * 2001-09-27 2003-04-10 Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
FR2838057B1 (fr) * 2002-04-05 2005-07-08 Servier Lab Nouvelle association d'un antithrombotique et d'aspirine
US20040067995A1 (en) * 2002-10-02 2004-04-08 Wong Pancras C. Novel combination of a factor Xa inhibitor and clopidogrel
US20050089473A1 (en) * 2003-09-10 2005-04-28 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
FR2860436B1 (fr) * 2003-10-03 2006-01-20 Servier Lab Nouvelle association d'un anti-atherothrombotique et d'un antiagregant plaquettaire
WO2005034867A2 (en) * 2003-10-09 2005-04-21 Millennium Pharmaceuticals, Inc. Thioether-substituted benzamides as inhibitors of factor xa
DE102004016845A1 (de) 2004-04-07 2005-10-27 Bayer Healthcare Ag Phenylthioessigsäure-Derivate und ihre Verwendung
CA2565437A1 (en) * 2004-06-18 2006-01-05 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
DE102004046623A1 (de) * 2004-09-25 2006-03-30 Bayer Healthcare Ag Neue Pyrimidin-Derivate und ihre Verwendung
DE102005027150A1 (de) * 2005-03-12 2006-09-28 Bayer Healthcare Ag Pyrimidincarbonsäure-Derivate und ihre Verwendung
WO2006137510A1 (ja) * 2005-06-24 2006-12-28 Ono Pharmaceutical Co., Ltd. 脳血管障害時における出血低減剤
US7598276B2 (en) * 2005-11-08 2009-10-06 Millenium Pharmaceuticals, Inc. Pharmaceutical salts and polymorphs of a factor Xa inhibitor
WO2007112367A2 (en) 2006-03-27 2007-10-04 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
EP2016072B1 (en) * 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
PT2404906E (pt) * 2006-11-02 2015-11-02 Millennium Pharm Inc Métodos de sintetizar sais farmacêuticos de um inibidor de fator xa
PT2101760E (pt) * 2006-12-08 2013-05-07 Millennium Pharm Inc Formulações de dose unitária e métodos de tratamento da trombose com um inibidor oral do fator xa
JP2010515691A (ja) * 2007-01-05 2010-05-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 第Ｘａ因子阻害剤
NZ581324A (en) * 2007-05-02 2012-05-25 Portola Pharm Inc Combination therapy with a compound acting as a platelet adp receptor inhibitor

Also Published As

Publication number Publication date
GT200900260A (es) 2011-09-05
BRPI0809655B8 (pt) 2021-05-25
KR101473207B1 (ko) 2014-12-16
US20080254036A1 (en) 2008-10-16
AU2008239659A1 (en) 2008-10-23
IL201433A0 (en) 2010-05-31
NZ580162A (en) 2012-10-26
HK1141230A1 (en) 2010-11-05
BRPI0809655B1 (pt) 2019-09-10
IL201433A (en) 2016-02-29
WO2008127682A3 (en) 2009-05-07
JP2013177459A (ja) 2013-09-09
EA200970946A1 (ru) 2010-04-30
CN101743001B (zh) 2013-02-06
US20130315897A1 (en) 2013-11-28
CA2683793C (en) 2016-09-20
EA020531B1 (ru) 2014-11-28
MX2009010953A (es) 2009-10-29
CN101743001A (zh) 2010-06-16
US8455440B2 (en) 2013-06-04
CA2683793A1 (en) 2008-10-23
CN103071154A (zh) 2013-05-01
EP2155195A2 (en) 2010-02-24
BRPI0809655A2 (pt) 2014-10-07
AU2008239659B2 (en) 2013-09-05
WO2008127682A2 (en) 2008-10-23
JP5469595B2 (ja) 2014-04-16
EP2591783A1 (en) 2013-05-15
EP2155195B1 (en) 2014-07-16
US20120046230A1 (en) 2012-02-23
KR20100016428A (ko) 2010-02-12
JP2010523679A (ja) 2010-07-15
DOP2009000244A (es) 2010-02-28

Similar Documents

Publication Publication Date Title
TN2009000408A1 (en) Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
EA200901442A1 (ru) Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
MX2010002353A (es) Amidas heterociclicas utiles para tratamiento de cancer y psoriais.
EA024702B8 (ru) Новые иммуномодуляторные и противовоспалительные соединения
PH12013502677A1 (en) Benzylamine derivatives as inhibitors of plasma kallikrein
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
EA201270215A1 (ru) Apaf-1 ингибиторные соединения
JO2870B1 (en) Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
MX356584B (es) Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.
GEP20146197B (en) New compounds
EA201000750A1 (ru) Производные 4-бензиламино-1-карбоксиацилпиперидина, как ингибиторы бпхэ (белка-переносчика холестериловогоэфира), применимые для лечения заболеваний, таких как гиперлипидемия или артериосклероз
MX2008012490A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
EA200802050A1 (ru) Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
MX2009007104A (es) Derivados de oxindol sustituido y su uso como ligandos del receptor de vasopresina.
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
TN2011000234A1 (en) Heterocyclically substituted aryl compounds as hif inhibitors
IN2012DN00721A (cg-RX-API-DMAC7.html)
MY186456A (en) Quinazoline carboxamide azetidines
ATE524450T1 (de) 5-phenyl-isoxazol-3-carboxamid-derivate als trpv1-modulatoren
EA201000098A1 (ru) Производные хиназолинамида
ATE456571T1 (de) Proteasom-hemmer und verwendungsverfahren dafür
MX2011009493A (es) Compuestos para el tratamiento de trastornos metabolicos.